_id
695fc25ac2e91020a7bd45a8
Ticker
0OB3.LSE
Name
Valneva SE
Exchange
LSE
Address
6 rue Alain Bombard, Saint-Herblain, France, 44800
Country
UK
Sector
Industry
Currency
EUR
Website
https://valneva.com
Description
Valneva SE, a specialty vaccine company, focused on the development and commercialization of prophylactic vaccines for infectious diseases with unmet needs. Its commercial vaccines for travelers include IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; and DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing Enterotoxigenic Escherichia coli bacterium. The company also develops VLA15, a vaccine candidate that is in Phase II clinical trial against Borrelia; VLA1553, a vaccine candidate, which is in Phase III clinical trial against the chikungunya virus; and VLA2001, a vaccine candidate that has completed Phase I/II clinical trial against SARS-CoV-2. It sells its products in the United States, Canada, Germany, Austria, Nordics, the United Kingdom, other European countries, and internationally. The company has collaborations with Pfizer to co-develop and commercialize its Lyme disease vaccine; and Instituto Butantan for the development, manufacturing, and marketing of single-shot chikungunya vaccine. Valneva SE was incorporated in 1999 and is headquartered in Saint-Herblain, France.
Last Close
4.26
Volume
26343
Current Price
4.31
Change
0.092
Last Updated
2026-01-08T14:42:34.057Z
Ipo Date
-
Market Cap
378541472
Next Dividend Date
-
Dividend Frequency
-
Dividend Rate
-
Dividend Yield
0
Sentiment
-
Sentiment Sources
0
Current Quarter
2025-09-30
Revenue
126971000
Cost Of Revenue
-71068000
Gross Profit
55903000
Operating Expenses
-58100000
Operating Income
-53945000
Interest Expense
17257000
Pretax Income
-63040000
Net Income
-65173000
Eps
-
Dividends Per Share
-
Shares Outstanding
76500000
Income Tax Expense
2133000
EBITDA
-
Operating Margin
-42.48607949846816
Total Other Income Expense Net
8020000
Cash
-
Short Term Investments
-
Receivables
-
Inventories
-
Total Current Assets
-
Property Plant Equipment
-
Total Assets
-
Payables
-
Short Term Debt
-
Long Term Debt
-
Total Liabilities
-
Equity
-
Bs_currency_symbol
-
Depreciation
-
Change In Working Capital
-
Cash From Operations
-
Capital Expenditures
-
Cash From Investing
-
Cash From Financing
-
Net Change In Cash
-
Cf_currency_symbol
-
PE
-
PB
-
ROE
-
ROA
-
FCF
-
Fcf Percent
-
Piotroski FScore
0
Health Score
45
Deep Value Investing Score
0
Defensive Investing Score
3
Dividend Investing Score
1.5
Economic Moat Investing Score
1.5
Garp Investing Score
2.5
Growth Investing Score
2.5
Momentum Investing Score
2
Net Net Investing Score
0
Quality Investing Score
0
Value Investing Score
0
Quarters > 0 > quarter
2025-09-30
Quarters > 0 > income Statement > revenue
126971000
Quarters > 0 > income Statement > cost Of Revenue
-71068000
Quarters > 0 > income Statement > gross Profit
55903000
Quarters > 0 > income Statement > operating Expenses
-58100000
Quarters > 0 > income Statement > operating Income
-53945000
Quarters > 0 > income Statement > interest Expense
17257000
Quarters > 0 > income Statement > pretax Income
-63040000
Quarters > 0 > income Statement > net Income
-65173000
Quarters > 0 > income Statement > eps
-
Quarters > 0 > income Statement > dividends Per Share
-
Quarters > 0 > income Statement > shares Outstanding
-
Quarters > 0 > income Statement > income Tax Expense
2133000
Quarters > 0 > income Statement > EBITDA
-
Quarters > 0 > income Statement > operating Margin
-42.48607949846816
Quarters > 0 > income Statement > total Other Income Expense Net
8020000
Quarters > 0 > income Statement > currency_symbol
-
Quarters > 0 > balance Sheet > cash
-
Quarters > 0 > balance Sheet > short Term Investments
-
Quarters > 0 > balance Sheet > receivables
-
Quarters > 0 > balance Sheet > inventories
-
Quarters > 0 > balance Sheet > total Current Assets
-
Quarters > 0 > balance Sheet > property Plant Equipment
-
Quarters > 0 > balance Sheet > total Assets
-
Quarters > 0 > balance Sheet > payables
-
Quarters > 0 > balance Sheet > short Term Debt
-
Quarters > 0 > balance Sheet > long Term Debt
-
Quarters > 0 > balance Sheet > total Liabilities
-
Quarters > 0 > balance Sheet > equity
-
Quarters > 0 > balance Sheet > currency_symbol
-
Quarters > 0 > cash Flow > net Income
-
Quarters > 0 > cash Flow > depreciation
-
Quarters > 0 > cash Flow > change In Working Capital
-
Quarters > 0 > cash Flow > cash From Operations
-
Quarters > 0 > cash Flow > capital Expenditures
-
Quarters > 0 > cash Flow > cash From Investing
-
Quarters > 0 > cash Flow > cash From Financing
-
Quarters > 0 > cash Flow > net Change In Cash
-
Quarters > 0 > cash Flow > currency_symbol
-
Quarters > 0 > ratios > PE
-
Quarters > 0 > ratios > PB
-
Quarters > 0 > ratios > ROE
-
Quarters > 0 > ratios > ROA
-
Quarters > 0 > ratios > FCF
-
Quarters > 0 > ratios > Piotroski FScore
0
Quarters > 0 > ratios > fcf Percent
-
Quarters > 0 > health Score
45
Quarters > 1 > quarter
2025-06-30
Quarters > 1 > income Statement > revenue
48330000
Quarters > 1 > income Statement > cost Of Revenue
24119000
Quarters > 1 > income Statement > gross Profit
24211000
Quarters > 1 > income Statement > operating Expenses
35081000
Quarters > 1 > income Statement > operating Income
-10870000
Quarters > 1 > income Statement > interest Expense
5606000
Quarters > 1 > income Statement > pretax Income
-11809000
Quarters > 1 > income Statement > net Income
-11586000
Quarters > 1 > income Statement > eps
-0.07134359371536463
Quarters > 1 > income Statement > dividends Per Share
-
Quarters > 1 > income Statement > shares Outstanding
162397202
Quarters > 1 > income Statement > income Tax Expense
-223000
Quarters > 1 > income Statement > EBITDA
-6203000
Quarters > 1 > income Statement > operating Margin
-22.49120629008897
Quarters > 1 > income Statement > total Other Income Expense Net
-939000
Quarters > 1 > income Statement > currency_symbol
-
Quarters > 1 > balance Sheet > cash
161307000
Quarters > 1 > balance Sheet > short Term Investments
-
Quarters > 1 > balance Sheet > receivables
24122000
Quarters > 1 > balance Sheet > inventories
61731000
Quarters > 1 > balance Sheet > total Current Assets
284717000
Quarters > 1 > balance Sheet > property Plant Equipment
147448000
Quarters > 1 > balance Sheet > total Assets
472625000
Quarters > 1 > balance Sheet > payables
5682000
Quarters > 1 > balance Sheet > short Term Debt
48669000
Quarters > 1 > balance Sheet > long Term Debt
-
Quarters > 1 > balance Sheet > total Liabilities
286193000
Quarters > 1 > balance Sheet > equity
186432000
Quarters > 1 > balance Sheet > currency_symbol
-
Quarters > 1 > cash Flow > net Income
-11586000
Quarters > 1 > cash Flow > depreciation
-
Quarters > 1 > cash Flow > change In Working Capital
978000
Quarters > 1 > cash Flow > cash From Operations
-2795000
Quarters > 1 > cash Flow > capital Expenditures
1255000
Quarters > 1 > cash Flow > cash From Investing
-681000
Quarters > 1 > cash Flow > cash From Financing
14881000
Quarters > 1 > cash Flow > net Change In Cash
8317000
Quarters > 1 > cash Flow > currency_symbol
EUR
Quarters > 1 > ratios > PE
-0.07134359371536463
Quarters > 1 > ratios > PB
3.754355156947305
Quarters > 1 > ratios > ROE
-6.214598352214212
Quarters > 1 > ratios > ROA
-2.451414969584766
Quarters > 1 > ratios > FCF
-4050000
Quarters > 1 > ratios > Piotroski FScore
1
Quarters > 1 > ratios > fcf Percent
-0.08379888268156424
Quarters > 1 > health Score
20
Quarters > 2 > quarter
2025-03-31
Quarters > 2 > income Statement > revenue
49232000
Quarters > 2 > income Statement > cost Of Revenue
23043000
Quarters > 2 > income Statement > gross Profit
26189000
Quarters > 2 > income Statement > operating Expenses
32149000
Quarters > 2 > income Statement > operating Income
-5960000
Quarters > 2 > income Statement > interest Expense
5979000
Quarters > 2 > income Statement > pretax Income
-7758000
Quarters > 2 > income Statement > net Income
-9232000
Quarters > 2 > income Statement > eps
-0.059999999870017334
Quarters > 2 > income Statement > dividends Per Share
-
Quarters > 2 > income Statement > shares Outstanding
153866667
Quarters > 2 > income Statement > income Tax Expense
1474000
Quarters > 2 > income Statement > EBITDA
-1779000
Quarters > 2 > income Statement > operating Margin
-12.105947351316217
Quarters > 2 > income Statement > total Other Income Expense Net
-1798000
Quarters > 2 > income Statement > currency_symbol
-
Quarters > 2 > balance Sheet > cash
152990000
Quarters > 2 > balance Sheet > short Term Investments
-
Quarters > 2 > balance Sheet > receivables
33524000
Quarters > 2 > balance Sheet > inventories
61680000
Quarters > 2 > balance Sheet > total Current Assets
287047000
Quarters > 2 > balance Sheet > property Plant Equipment
154310000
Quarters > 2 > balance Sheet > total Assets
482242000
Quarters > 2 > balance Sheet > payables
27835000
Quarters > 2 > balance Sheet > short Term Debt
22404000
Quarters > 2 > balance Sheet > long Term Debt
-
Quarters > 2 > balance Sheet > total Liabilities
306989000
Quarters > 2 > balance Sheet > equity
175253000
Quarters > 2 > balance Sheet > currency_symbol
-
Quarters > 2 > cash Flow > net Income
-9232000
Quarters > 2 > cash Flow > depreciation
-
Quarters > 2 > cash Flow > change In Working Capital
-8766000
Quarters > 2 > cash Flow > cash From Operations
-8148000
Quarters > 2 > cash Flow > capital Expenditures
1473000
Quarters > 2 > cash Flow > cash From Investing
-961000
Quarters > 2 > cash Flow > cash From Financing
-5582000
Quarters > 2 > cash Flow > net Change In Cash
-15281000
Quarters > 2 > cash Flow > currency_symbol
EUR
Quarters > 2 > ratios > PE
-0.059999999870017334
Quarters > 2 > ratios > PB
3.78404554997632
Quarters > 2 > ratios > ROE
-5.267812819181412
Quarters > 2 > ratios > ROA
-1.9143915295639948
Quarters > 2 > ratios > FCF
-9621000
Quarters > 2 > ratios > Piotroski FScore
1
Quarters > 2 > ratios > fcf Percent
-0.19542167695807605
Quarters > 2 > health Score
20
Quarters > 3 > quarter
2024-12-31
Quarters > 3 > income Statement > revenue
52941000
Quarters > 3 > income Statement > cost Of Revenue
27232000
Quarters > 3 > income Statement > gross Profit
25709000
Quarters > 3 > income Statement > operating Expenses
46593000
Quarters > 3 > income Statement > operating Income
-20884000
Quarters > 3 > income Statement > interest Expense
6271000
Quarters > 3 > income Statement > pretax Income
-32348000
Quarters > 3 > income Statement > net Income
-36987000
Quarters > 3 > income Statement > eps
-0.22775638708356563
Quarters > 3 > income Statement > dividends Per Share
-
Quarters > 3 > income Statement > shares Outstanding
162397202
Quarters > 3 > income Statement > income Tax Expense
4639000
Quarters > 3 > income Statement > EBITDA
-26077000
Quarters > 3 > income Statement > operating Margin
-39.44768704784571
Quarters > 3 > income Statement > total Other Income Expense Net
-11464000
Quarters > 3 > income Statement > currency_symbol
-
Quarters > 3 > balance Sheet > cash
168270000
Quarters > 3 > balance Sheet > short Term Investments
-
Quarters > 3 > balance Sheet > receivables
35205000
Quarters > 3 > balance Sheet > inventories
53663000
Quarters > 3 > balance Sheet > total Current Assets
299012000
Quarters > 3 > balance Sheet > property Plant Equipment
158115000
Quarters > 3 > balance Sheet > total Assets
500032000
Quarters > 3 > balance Sheet > payables
12639000
Quarters > 3 > balance Sheet > short Term Debt
23360000
Quarters > 3 > balance Sheet > long Term Debt
-
Quarters > 3 > balance Sheet > total Liabilities
318779000
Quarters > 3 > balance Sheet > equity
181253000
Quarters > 3 > balance Sheet > currency_symbol
-
Quarters > 3 > cash Flow > net Income
-36987000
Quarters > 3 > cash Flow > depreciation
305000
Quarters > 3 > cash Flow > change In Working Capital
23681000
Quarters > 3 > cash Flow > cash From Operations
9526000
Quarters > 3 > cash Flow > capital Expenditures
3859000
Quarters > 3 > cash Flow > cash From Investing
4688000
Quarters > 3 > cash Flow > cash From Financing
-4590000
Quarters > 3 > cash Flow > net Change In Cash
11936000
Quarters > 3 > cash Flow > currency_symbol
EUR
Quarters > 3 > ratios > PE
-0.22775638708356563
Quarters > 3 > ratios > PB
3.861629548862639
Quarters > 3 > ratios > ROE
-20.40628293048943
Quarters > 3 > ratios > ROA
-7.396926596697812
Quarters > 3 > ratios > FCF
5667000
Quarters > 3 > ratios > Piotroski FScore
2
Quarters > 3 > ratios > fcf Percent
0.10704369014563382
Quarters > 3 > health Score
29
Annuals > 0 > quarter
2024-12-31
Annuals > 0 > income Statement > revenue
169578000
Annuals > 0 > income Statement > cost Of Revenue
98538000
Annuals > 0 > income Statement > gross Profit
71040000
Annuals > 0 > income Statement > operating Expenses
57710000
Annuals > 0 > income Statement > operating Income
13330000
Annuals > 0 > income Statement > interest Expense
23984000
Annuals > 0 > income Statement > pretax Income
-11486000
Annuals > 0 > income Statement > net Income
-12247000
Annuals > 0 > income Statement > eps
-0.08405289022111916
Annuals > 0 > income Statement > dividends Per Share
-
Annuals > 0 > income Statement > shares Outstanding
145705876
Annuals > 0 > income Statement > income Tax Expense
761000
Annuals > 0 > income Statement > EBITDA
32084000
Annuals > 0 > income Statement > operating Margin
7.860689476229228
Annuals > 0 > income Statement > total Other Income Expense Net
-24816000
Annuals > 0 > income Statement > currency_symbol
-
Annuals > 0 > balance Sheet > cash
168270000
Annuals > 0 > balance Sheet > short Term Investments
-
Annuals > 0 > balance Sheet > receivables
35205000
Annuals > 0 > balance Sheet > inventories
53663000
Annuals > 0 > balance Sheet > total Current Assets
299012000
Annuals > 0 > balance Sheet > property Plant Equipment
158115000
Annuals > 0 > balance Sheet > total Assets
500032000
Annuals > 0 > balance Sheet > payables
12639000
Annuals > 0 > balance Sheet > short Term Debt
23360000
Annuals > 0 > balance Sheet > long Term Debt
-
Annuals > 0 > balance Sheet > total Liabilities
318779000
Annuals > 0 > balance Sheet > equity
181253000
Annuals > 0 > balance Sheet > currency_symbol
-
Annuals > 0 > cash Flow > net Income
-12247000
Annuals > 0 > cash Flow > depreciation
19586000
Annuals > 0 > cash Flow > change In Working Capital
-11394000
Annuals > 0 > cash Flow > cash From Operations
-67218000
Annuals > 0 > cash Flow > capital Expenditures
16444000
Annuals > 0 > cash Flow > cash From Investing
76916000
Annuals > 0 > cash Flow > cash From Financing
30682000
Annuals > 0 > cash Flow > net Change In Cash
42191000
Annuals > 0 > cash Flow > currency_symbol
-
Annuals > 0 > ratios > PE
-0.08405289022111916
Annuals > 0 > ratios > PB
3.4647278972485966
Annuals > 0 > ratios > ROE
-6.756853679663233
Annuals > 0 > ratios > ROA
-2.4492432484321003
Annuals > 0 > ratios > FCF
-83662000
Annuals > 0 > ratios > Piotroski FScore
1
Annuals > 0 > ratios > fcf Percent
-0.493354090742903
Annuals > 0 > health Score
20
Annuals > 1 > quarter
2023-12-31
Annuals > 1 > income Statement > revenue
153712000
Annuals > 1 > income Statement > cost Of Revenue
100875000
Annuals > 1 > income Statement > gross Profit
52837000
Annuals > 1 > income Statement > operating Expenses
134924000
Annuals > 1 > income Statement > operating Income
-82087000
Annuals > 1 > income Statement > interest Expense
23325000
Annuals > 1 > income Statement > pretax Income
-98629000
Annuals > 1 > income Statement > net Income
-101429000
Annuals > 1 > income Statement > eps
-0.7316822572502596
Annuals > 1 > income Statement > dividends Per Share
-
Annuals > 1 > income Statement > shares Outstanding
138624381
Annuals > 1 > income Statement > income Tax Expense
2800000
Annuals > 1 > income Statement > EBITDA
-57720000
Annuals > 1 > income Statement > operating Margin
-53.40311751847611
Annuals > 1 > income Statement > total Other Income Expense Net
-16542000
Annuals > 1 > income Statement > currency_symbol
-
Annuals > 1 > balance Sheet > cash
126080000
Annuals > 1 > balance Sheet > short Term Investments
-
Annuals > 1 > balance Sheet > receivables
41645000
Annuals > 1 > balance Sheet > inventories
44466000
Annuals > 1 > balance Sheet > total Current Assets
262824000
Annuals > 1 > balance Sheet > property Plant Equipment
156590000
Annuals > 1 > balance Sheet > total Assets
460062000
Annuals > 1 > balance Sheet > payables
17564000
Annuals > 1 > balance Sheet > short Term Debt
46958000
Annuals > 1 > balance Sheet > long Term Debt
-
Annuals > 1 > balance Sheet > total Liabilities
331815000
Annuals > 1 > balance Sheet > equity
128247000
Annuals > 1 > balance Sheet > currency_symbol
-
Annuals > 1 > cash Flow > net Income
-101429000
Annuals > 1 > cash Flow > depreciation
17584000
Annuals > 1 > cash Flow > change In Working Capital
-145064000
Annuals > 1 > cash Flow > cash From Operations
-202744000
Annuals > 1 > cash Flow > capital Expenditures
14231000
Annuals > 1 > cash Flow > cash From Investing
-20585000
Annuals > 1 > cash Flow > cash From Financing
63081000
Annuals > 1 > cash Flow > net Change In Cash
-160452000
Annuals > 1 > cash Flow > currency_symbol
EUR
Annuals > 1 > ratios > PE
-0.7316822572502596
Annuals > 1 > ratios > PB
4.65875289176355
Annuals > 1 > ratios > ROE
-79.08878960131621
Annuals > 1 > ratios > ROA
-22.0468110819846
Annuals > 1 > ratios > FCF
-216975000
Annuals > 1 > ratios > Piotroski FScore
1
Annuals > 1 > ratios > fcf Percent
-1.4115683876340168
Annuals > 1 > health Score
16
Annuals > 2 > quarter
2022-12-31
Annuals > 2 > income Statement > revenue
361303000
Annuals > 2 > income Statement > cost Of Revenue
324441000
Annuals > 2 > income Statement > gross Profit
36862000
Annuals > 2 > income Statement > operating Expenses
150305000
Annuals > 2 > income Statement > operating Income
-113443000
Annuals > 2 > income Statement > interest Expense
19054000
Annuals > 2 > income Statement > pretax Income
-144815000
Annuals > 2 > income Statement > net Income
-143279000
Annuals > 2 > income Statement > eps
-1.240791058662825
Annuals > 2 > income Statement > dividends Per Share
-
Annuals > 2 > income Statement > shares Outstanding
115473914
Annuals > 2 > income Statement > income Tax Expense
-1536000
Annuals > 2 > income Statement > EBITDA
-104725000
Annuals > 2 > income Statement > operating Margin
-31.398300041793174
Annuals > 2 > income Statement > total Other Income Expense Net
-31372000
Annuals > 2 > income Statement > currency_symbol
-
Annuals > 2 > balance Sheet > cash
289430000
Annuals > 2 > balance Sheet > short Term Investments
-
Annuals > 2 > balance Sheet > receivables
23912000
Annuals > 2 > balance Sheet > inventories
35104000
Annuals > 2 > balance Sheet > total Current Assets
424659000
Annuals > 2 > balance Sheet > property Plant Equipment
154038000
Annuals > 2 > balance Sheet > total Assets
621344000
Annuals > 2 > balance Sheet > payables
14505000
Annuals > 2 > balance Sheet > short Term Debt
36991000
Annuals > 2 > balance Sheet > long Term Debt
-
Annuals > 2 > balance Sheet > total Liabilities
401547000
Annuals > 2 > balance Sheet > equity
219797000
Annuals > 2 > balance Sheet > currency_symbol
-
Annuals > 2 > cash Flow > net Income
-143279000
Annuals > 2 > cash Flow > depreciation
21036000
Annuals > 2 > cash Flow > change In Working Capital
-145981000
Annuals > 2 > cash Flow > cash From Operations
-245343000
Annuals > 2 > cash Flow > capital Expenditures
29322000
Annuals > 2 > cash Flow > cash From Investing
-29054000
Annuals > 2 > cash Flow > cash From Financing
215116000
Annuals > 2 > cash Flow > net Change In Cash
-57212000
Annuals > 2 > cash Flow > currency_symbol
EUR
Annuals > 2 > ratios > PE
-1.240791058662825
Annuals > 2 > ratios > PB
2.2643283090306054
Annuals > 2 > ratios > ROE
-65.18696797499511
Annuals > 2 > ratios > ROA
-23.059529020961016
Annuals > 2 > ratios > FCF
-274665000
Annuals > 2 > ratios > Piotroski FScore
1
Annuals > 2 > ratios > fcf Percent
-0.7602068070290033
Annuals > 2 > health Score
25
Annuals > 3 > quarter
2021-12-31
Annuals > 3 > income Statement > revenue
348085000
Annuals > 3 > income Statement > cost Of Revenue
187920000
Annuals > 3 > income Statement > gross Profit
160165000
Annuals > 3 > income Statement > operating Expenses
221556000
Annuals > 3 > income Statement > operating Income
-61391000
Annuals > 3 > income Statement > interest Expense
16963000
Annuals > 3 > income Statement > pretax Income
-69979000
Annuals > 3 > income Statement > net Income
-73425000
Annuals > 3 > income Statement > eps
-0.7521564378854514
Annuals > 3 > income Statement > dividends Per Share
-
Annuals > 3 > income Statement > shares Outstanding
97619320
Annuals > 3 > income Statement > income Tax Expense
3446000
Annuals > 3 > income Statement > EBITDA
-38735000
Annuals > 3 > income Statement > operating Margin
-17.636784118821552
Annuals > 3 > income Statement > total Other Income Expense Net
-8589000
Annuals > 3 > income Statement > currency_symbol
-
Annuals > 3 > balance Sheet > cash
346642000
Annuals > 3 > balance Sheet > short Term Investments
-
Annuals > 3 > balance Sheet > receivables
44013000
Annuals > 3 > balance Sheet > inventories
124098000
Annuals > 3 > balance Sheet > total Current Assets
585833000
Annuals > 3 > balance Sheet > property Plant Equipment
173831000
Annuals > 3 > balance Sheet > total Assets
817352000
Annuals > 3 > balance Sheet > payables
16035000
Annuals > 3 > balance Sheet > short Term Debt
10242000
Annuals > 3 > balance Sheet > long Term Debt
-
Annuals > 3 > balance Sheet > total Liabilities
646771000
Annuals > 3 > balance Sheet > equity
170581000
Annuals > 3 > balance Sheet > currency_symbol
-
Annuals > 3 > cash Flow > net Income
-73425000
Annuals > 3 > cash Flow > depreciation
14281000
Annuals > 3 > cash Flow > change In Working Capital
36127000
Annuals > 3 > cash Flow > cash From Operations
76901000
Annuals > 3 > cash Flow > capital Expenditures
93171000
Annuals > 3 > cash Flow > cash From Investing
-93116000
Annuals > 3 > cash Flow > cash From Financing
154504000
Annuals > 3 > cash Flow > net Change In Cash
142292000
Annuals > 3 > cash Flow > currency_symbol
EUR
Annuals > 3 > ratios > PE
-0.7521564378854514
Annuals > 3 > ratios > PB
2.466507226478916
Annuals > 3 > ratios > ROE
-43.044067041464174
Annuals > 3 > ratios > ROA
-8.983277706545039
Annuals > 3 > ratios > FCF
-16270000
Annuals > 3 > ratios > Piotroski FScore
2
Annuals > 3 > ratios > fcf Percent
-0.0467414568280736
Annuals > 3 > health Score
18
Valuation > final Score
50
Valuation > verdict
Fair
Profitability > metrics > Net Margin
-0.5132904363988627
Profitability > final Score
35
Profitability > verdict
Weak
Risk > metrics > Interest Coverage
-3.125977864055166
Risk > final Score
17
Risk > verdict
High
Liquidity > final Score
50
Liquidity > verdict
Weak
Prev Valuations > 0
42.45644843052695
Prev Valuations > 1
42.159544500236805
Prev Valuations > 2
41.38370451137361
Prev Profitabilities > 0
0
Prev Profitabilities > 1
0
Prev Profitabilities > 2
0
Prev Risks > 0
22
Prev Risks > 1
26
Prev Risks > 2
17
Prev Liquidities > 0
100
Prev Liquidities > 1
100
Prev Liquidities > 2
100
Updated At
2026-01-20T23:14:18.559Z
Earnings History > 0 > period
2025-12-31
Earnings History > 0 > report Date
2026-03-19
Earnings History > 0 > date
2025-12-31
Earnings History > 0 > before After Market
AfterMarket
Earnings History > 0 > currency
-
Earnings History > 0 > eps Actual
-
Earnings History > 0 > eps Estimate
-
Earnings History > 0 > eps Difference
0
Earnings History > 0 > surprise Percent
-
Valneva SE, a specialty vaccine company, focused on the development and commercialization of prophylactic vaccines for infectious diseases with unmet needs. Its commercial vaccines for travelers include IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; and DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing Enterotoxigenic Escherichia coli bacterium. The company also develops VLA15, a vaccine candidate that is in Phase II clinical trial against Borrelia; VLA1553, a vaccine candidate, which is in Phase III clinical trial against the chikungunya virus; and VLA2001, a vaccine candidate that has completed Phase I/II clinical trial against SARS-CoV-2. It sells its products in the United States, Canada, Germany, Austria, Nordics, the United Kingdom, other European countries, and internationally. The company has collaborations with Pfizer to co-develop and commercialize its Lyme disease vaccine; and Instituto Butantan for the development, manufacturing, and marketing of single-shot chikungunya vaccine. Valneva SE was incorporated in 1999 and is headquartered in Saint-Herblain, France.
Stock Price
€0.00
increase compared to yesterday.
Dividend
Frequency:
Rate:
N/ANext Payout:
N/A(Last Updated 2025-09-30)
Health Score
* Institutions hold a combined 0.00% of the total shares of Valneva SE
* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.
Date
2025-12-31
EPS Estimate
—
Date
—
EPS Actual
—
EPS Estimate
—
EPS Difference
—
Surprise Percent
undefined%
(Last Updated 2025-09-30)
(Last Updated 2025-09-30)
Revenue
€ 0
Cost Of Revenue
€ 0
Gross Profit
€ 0
Operating Expenses
€ 0
Operating Income
€ 0
Interest Expense
€ 0
Pretax Income
€ 0
Net Income
€ 0
Income Tax Expense
€ 0
EBITDA
€ 0
Total Other Income Expense Net
€ 0
Earnings Per Share
0
Dividends Per Share
0
Shares Outstanding
0
Operating Margin
0%
(Last Updated 2025-09-30)
Cash
€ 0
Short Term Investments
€ 0
Receivables
€ 0
Inventories
€ 0
Total Current Assets
€ 0
Property Plant Equipment
€ 0
Total Assets
€ 0
Payables
€ 0
Short Term Debt
€ 0
Long Term Debt
€ 0
Total Liabilities
€ 0
Equity
€ 0
(Last Updated 2025-09-30)
Net Income
€ 0
Depreciation
€ 0
Change In Working Capital
€ 0
Cash From Operations
€ 0
Capital Expenditures
€ 0
Cash From Investing
€ 0
Cash From Financing
€ 0
Net Change In Cash
€ 0
Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.